On 29 May, Acutus Medical and Biotronik announced that they had entered a partnership to collaborate on certain electrophysiology-related products. This positive news comes as restrictions put in place due to Covid-19 begin to ease around the world.
Biotronik, a Germany-based medical device manufacturer, already produces a suite of devices for cardiac rhythm management (CRM) that largely focuses on implantable devices. Biotronik is a major player in the Cardiac Resynchronization Therapy, Implantable Cardioverter Defibrillator, and Pacemaker markets, which were valued globally at $2.5bn, $2.4bn, and $2.7bn in 2019 respectively.
Biotronik is adding to its existing CRM portfolio by partnering with Acutus Medical. This partnership is largely centered on Acutus Medical’s AcQMap system. This product offers a non-contact method for mapping heart rhythms, allowing physicians to identify changes in electrophysiological conduction patterns while carrying out electrophysiology procedures. Under the partnership, Acutus Medical will market Biotronik’s existing electrophysiology ablation products under a private label. Together with the AcQMap system, these products will offer physicians a complete system for electrophysiology procedures.
GlobalData estimates that approximately 3.7 million people in the US are suffering from atrial fibrillation in 2020, and expects that number to grow to 4.8 million by 2030. By partnering together, Biotronik and Acutus Medical offer a powerful clinical solution for the millions of people around the world suffering from atrial fibrillation, as well as many other heart rhythm disorders.
The partnership between these two companies is also coming at a relatively good time, as the number of Covid-19 patients is beginning to stabilize in many countries, and governments around the world are preparing and implementing plans to ease restrictions that were put into place during the Covid-19 pandemic. As many electrophysiology procedures were delayed or cancelled due to Covid-19, these procedures will now need to be rescheduled, leading to a surge in procedures that could use the Biotronik/Acutus Medical system. GlobalData forecasts that these companies will see a boost in sales mirroring the boost in electrophysiology procedures around the world post-Covid-19.